Recent Updates
Recently added Catalysts
EXEL Positive Sentiment

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wednesday, August 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Exelixis, Inc. has announced its financial results for the second quarter of 2026, highlighting progress in achieving corporate objectives. The company is focused on its strategic goals and has outlined milestones in its commercial, clinical, and pipeline development. CEO Michael M. Morrissey emphasized the company's commitment to executing its business strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exelixis reported strong financial results for Q2 2026.
  • The company is on track to meet its strategic objectives.
  • There are ongoing developments in commercial, clinical, and pipeline areas.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
2.5%
average across 7 past catalysts
Lead asset
XL309
Phase 1 · Advanced Solid Tumor

Full Press Release Details

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 and beyond,” said Michael M. Morrissey, Ph.D., President and Chief Executive O

Frequently Asked Questions

What were Exelixis' financial results for Q2 2026?

Exelixis reported strong financial results for the second quarter of 2026.

What corporate objectives did Exelixis outline?

Exelixis provided an update on progress toward achieving key corporate objectives.

Who is the CEO of Exelixis?

Michael M. Morrissey, Ph.D., is the President and CEO of Exelixis.

What areas are Exelixis focusing on?

The company is focusing on commercial, clinical, and pipeline development milestones.

ShareAdd on Google
Tags: EXEL Viatris Investor Conferences Healthcare Exelixis financial results Q2 2026 corporate update clinical milestones
Last updated: Aug 5, 2026

Biotech snapshot

Cash runway
$1426M liquidity · $0M/mo burn
Low dilution risk
Lead asset
XL309Phase 1
Advanced Solid Tumor →

Catalyst track record

+40%
best trade around EXEL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for EXEL.

See every catalyst's timing & PoA →